Thus, using COMT inhibitors, entacapone and tolcapone, decreased the deposition of α-synuclein and β-amyloid proteins, thereby reducing their induced neurotoxicity and significantly improving the cognitive function of AD and PD patients [47, 48]. The gene discussed is COMT; the disease is Alzheimer disease.